期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新喹诺酮类药物治疗社区获得性肺炎的研究进展 被引量：7

下载PDF
导出
摘要 新喹诺酮类药物治疗社区获得性肺炎(CAP)疗效较好。笔者通过检索、查阅国内外文献,分析、归纳了新喹诺酮类药物的抗菌作用和药效学特点,及其在治疗CAP中的疗效、地位。
作者 于霞 林忠嗣
机构地区 辽宁中医药大学第二附属医院
出处 《实用药物与临床》 CAS 2008年第5期309-310,324,共3页 Practical Pharmacy and Clinical Remedies
关键词 新喹诺酮类药物 社区获得性肺炎(CAP) 临床研究 治疗方法
分类号 R563.1 [医药卫生—呼吸系统]
  • 相关文献

参考文献14

  • 1Read RC, Morrissey I, Ambler JE, et al. Clinicians manual on respiratory tract infections and fluoroquinolones[M]. London: Science Press Ltd, 2005 : 29-30.
  • 2林赴田.氟喹诺酮类抗菌药的药理和临床研究进展[J].国外医药（抗生素分册）,2001,22(6):247-252. 被引量：14
  • 3Wish R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract[J ]. European Respir J, 2006, 14 (1) : 221-223.
  • 4Sullivan JG, McElroy A, Honsinger RW, et al. A double-blind, randomized study of safety and efficacy treating community acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[ J ]. J Respir Dis, 2004, 20: 49-50.
  • 5Forgarty C, Dowell ME, EUison WT, et al. A prospective, randomized, double-blind study treating community-acquired pneumonia in hospitalized patients gatifloxacin vs ceftriaxone/Clarithromycin[ J ]. J Respir Dis, 2006, 20: 60-61.
  • 6Ball P, Wilson R, Mandell L, et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double- blind comparison with trovafloxacin[J] .J Chemother, 2003, 13 (3) :288-289.
  • 7Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia, diagnosis, assessment of severity, antimicrobial therapy, and prevention[J ].Am J Respir Crit Care Med, 2005,163:1730-1754.
  • 8王睿,方翼,刘庆锋,夏焱,马红莲.甲磺酸左氧氟沙星与环丙沙星体外抗生素后效应的比较[J].中华内科杂志,2000,39(3):199-199. 被引量：7
  • 9张歆刚,刘又宁,王睿.丁胺卡那霉素日剂量单次与分两次给药方案的体内药效及毒性比较[J].中华医学杂志,2002,82(5):356-358. 被引量：20
  • 10陈胜昔,郭惠元.新的广谱、高效喹诺酮类抗菌药gemifloxacin[J].国外医药（抗生素分册）,2002,23(6):279-283. 被引量：11

二级参考文献36

  • 1雷军,王浴生.氟喳诺酮药物每日一剂疗法[J].国外医药（抗生素分册）,1996,17(1):56-59. 被引量：45
  • 2全国肺心病协作组.慢性肺原性心脏病诊断标准[J].中华结核和呼吸系疾病杂志,1978,1:56-57.
  • 3[1]Morrissey I, George JT. Purification of pneumococcal type Ⅱ topoisomerases and inhibition by gemifloxacin and other quinolones. [J]. JAntimicrob Chemother, 2000, 45(Suppl S1):101
  • 4[2]Hardy D, Amsterdam D, Mandell LA, et al. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. [J]. Antimicrob Agents Chemother, 2000, 44(2):802
  • 5[3]Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphyridone. [J]. Antimicrob Agents Chemother, 1997, 41(1): 200
  • 6[4]Goldstein EJC, Citron DM, Warren Y, et al. In vitro activity of gemifloxacin (SB 265805) against anaerobes. [J]. Anfimicrob Agents Chemother, 1999, 43(9): 2231-2235
  • 7[5]Dubois J, St-Pierre C. Comparative in vitro potency and post-antibiotic effect of gemifloxacin against Legionella spp. [J]. J Antimicrob Chemother, 2000, 45 (suppl. S1): 41
  • 8[6]Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent chnical isolates of Chlamydia pneumoniae. [J]. Antimicrob Agents Chemother, 1999, 43(11):2806
  • 9[7]Oh JI, Paek KS, Ahn MJ, et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. [J]. Antimicrob Agents Chemother, 1996, 40(6): 156 4
  • 10[8]Berry V, Page R, Satterfield J, et al. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. [J]. J Antimicrob Chemother, 2000,45(Suppl S1):79

共引文献73

同被引文献65

引证文献7

二级引证文献26

实用药物与临床
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部